Therapeutic potential of CDK11 in cancer
Clinical and Translational Medicine · 2023-03 · 13 (3)
DOI: 10.1002/ctm2.1201 ↗At a glance
Kommentar in Clinical and Translational Medicine, published online on 2023-02-28. Written by Dalibor Blazek. Institution: Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Major MEDLINE topics: Cyclin-Dependent Kinases, Neoplasms. Cited 22 times so far (Crossref); 12 references. The full text is freely available (open access, CC BY 4.0). Funded by: the Czech Science Foundation.
Abstract (original language)
Human cyclin‐dependent kinases (CDKs) direct the progression of the cell cycle and transcription. They are deregulated in tumours, and despite their involvement in the regulation of basic cellular processes, many CDKs are promising targets for cancer therapy. CDK11 is an essential gene for the growth of many malignancies; however, its primary cellular function has been obscure, and the mode‐of‐action of OTS964, the first CDK11 inhibitor and antiproliferative compound, has been unknown. A recent study has shown that OTS964 prevents spliceosome activation, revealing a key role of CDK11 in the regulation of pre‐mRNA splicing. In light of these findings, we discuss the therapeutic potential of CDK11 in cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
ORCID profiles: Dalibor Blazek
Funding
- the Czech Science Foundation
Cite
APA
Blazek, D. (2023). Therapeutic potential of CDK11 in cancer. Clinical and Translational Medicine, 13(3). https://doi.org/10.1002/ctm2.1201
Vancouver
Blazek D. Therapeutic potential of CDK11 in cancer. Clinical and Translational Medicine. 2023;13(3). doi:10.1002/ctm2.1201
BibTeX
@article{Blazek2023,
author = {Blazek, Dalibor},
title = {Therapeutic potential of CDK11 in cancer},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {3},
doi = {10.1002/ctm2.1201}
}
EUVIMED